β-Blocker Therapy Is Not Associated With Adverse Outcomes in Patients With Pulmonary Arterial Hypertension

A Propensity Score Analysis

Thenappan Thenappan, MD; Samit S. Roy, MSPH; Sue Duval, PhD; Cherylanne Glassner-Kolmin, BS, MPH; Mardi Gomberg-Maitland, MD, MSc

Background—The safety of β-blockers in patients with isolated right ventricular failure because of pulmonary arterial hypertension (PAH) is unclear.

Methods and Results—We studied 564 PAH patients (total cohort) referred to our center from 1982 to 2013. Propensity score-matching was used to match pairs of PAH patients with and without β-blocker use (matched cohort). We compared all-cause mortality between the groups in the total cohort and the matched cohort using bootstrap validation, Kaplan–Meier, and Cox proportional hazard analyses. Seventy-one of the 564 patients in the total cohort were on β-blockers. They were older, had higher prevalence of comorbidities, and were more often on diuretics, digoxin, and angiotensin converting enzyme inhibitors. The severity of PAH and right ventricular failure was similar between those with and without β-blocker use. After propensity matching, 63 patients with β-blocker use were compared with 51 patients without β-blocker use. During a median follow-up time of 4.8 years, there were 339 (60%) deaths in the total cohort and 70 deaths (61%) in the matched cohort. There was no difference in absolute mortality between those with and without β-blocker use. During a median follow-up time of 4.8 years, there were 339 (60%) deaths in the total cohort and 70 deaths (61%) in the matched cohort. There was no difference in absolute mortality between those with and without β-blocker use. During a median follow-up time of 4.8 years, there were 339 (60%) deaths in the total cohort and 70 deaths (61%) in the matched cohort. There was no difference in absolute mortality between those with and without β-blocker use. During a median follow-up time of 4.8 years, there were 339 (60%) deaths in the total cohort and 70 deaths (61%) in the matched cohort. There was no difference in absolute mortality between those with and without β-blocker use. During a median follow-up time of 4.8 years, there were 339 (60%) deaths in the total cohort and 70 deaths (61%) in the matched cohort. There was no difference in absolute mortality between those with and without β-blocker use. During a median follow-up time of 4.8 years, there were 339 (60%) deaths in the total cohort and 70 deaths (61%) in the matched cohort. There was no difference in absolute mortality between those with and without β-blocker use. During a median follow-up time of 4.8 years, there were 339 (60%) deaths in the total cohort and 70 deaths (61%) in the matched cohort. There was no difference in absolute mortality between those with and without β-blocker use. During a median follow-up time of 4.8 years, there were 339 (60%) deaths in the total cohort and 70 deaths (61%) in the matched cohort. There was no difference in absolute mortality between those with and without β-blocker use. During a median follow-up time of 4.8 years, there were 339 (60%) deaths in the total cohort and 70 deaths (61%) in the matched cohort. There was no difference in absolute mortality between those with and without β-blocker use. During a median follow-up time of 4.8 years, there were 339 (60%) deaths in the total cohort and 70 deaths (61%) in the matched cohort. There was no difference in absolute mortality between those with and without β-blocker use. During a median follow-up time of 4.8 years, there were 339 (60%) deaths in the total cohort and 70 deaths (61%) in the matched cohort. There was no difference in absolute mortality between those with and without β-blocker use. During a median follow-up time of 4.8 years, there were 339 (60%) deaths in the total cohort and 70 deaths (61%) in the matched cohort. There was no difference in absolute mortality between those with and without β-blocker use. During a median follow-up time of 4.8 years, there were 339 (60%) deaths in the total cohort and 70 deaths (61%) in the matched cohort. There was no difference in absolute mortality between those with and without β-blocker use. During a median follow-up time of 4.8 years, there were 339 (60%) deaths in the total cohort and 70 deaths (61%) in the matched cohort. There was no difference in absolute mortality between those with and without β-blocker use. During a median follow-up time of 4.8 years, there were 339 (60%) deaths in the total cohort and 70 deaths (61%) in the matched cohort. There was no difference in absolute mortality between those with and without β-blocker use. During a median follow-up time of 4.8 years, there were 339 (60%) deaths in the total cohort and 70 deaths (61%) in the matched cohort. There was no difference in absolute mortality between those with and without β-blocker use. During a median follow-up time of 4.8 years, there were 339 (60%) deaths in the total cohort and 70 deaths (61%) in the matched cohort.

Conclusions—There was no statistically significant difference in long-term mortality between propensity score-matched pairs of PAH patients with and without β-blocker use. These findings need further validation in prospective clinical trials. (Circ Heart Fail. 2014;7:903-910.)

Key Words: adrenergic blockers ■ heart failure ■ pulmonary hypertension ■ right ventricle

Pulmonary arterial hypertension (PAH) is a debilitating disease characterized by progressive narrowing of the resistance pulmonary arteries, ultimately leading to right ventricular failure (RVF) and death.1 Despite progress in understanding the pathogenesis and treatment of PAH, incident cases continue to have a 1-year mortality rate of ≈15%.2–4 Initially, the right ventricle hypertrophies in PAH as an adaptive response to the increased afterload with preserved contractile function. As the disease progresses, the right ventricle dilates because of maladaptive remodeling and eventually fails.5 Long-term outcomes in PAH are largely determined by the response of the right ventricle to the increased afterload.5 Right ventricular (RV) function is the major determinant of functional capacity and survival in patients with PAH.2–4,6,7

Clinical Perspective on p 910

Increased cardiac adrenergic drive leads to left ventricular dilation, remodeling, and eventually failure in patients with left ventricular systolic dysfunction.8 Pharmacological blockade of the β-adrenergic receptor with β-blockers is one of the main treatment strategies in left ventricular systolic dysfunction.9 Multiple large, randomized, double-blind, controlled trials have demonstrated that long-term β-blockade therapy in left ventricular systolic dysfunction improves cardiac function and reduces maladaptive ventricular remodeling and sudden arrhythmias, ultimately leading to improved quality of life and survival.10–12

The safety and efficacy of β-blocker therapy in isolated RVF associated with PAH is unclear. There is a theoretical concern for worsening RVF with β-blocker therapy in patients with PAH, as they are highly dependent on the heart rate to maintain their cardiac output (CO).13 However, preclinical animal studies have demonstrated increased survival with β-blocker therapy in experimental PAH.14–16 Currently, β-blockers are often used to treat concomitant cardiovascular disease in PAH patients. Human studies have reported conflicting results with respect to the efficacy of β-blockers in patients with PAH.17,18

Thus, in this study, we sought to determine the association between β-blocker therapy and long-term adverse outcomes in patients with PAH and to evaluate the safety of β-blocker therapy in PAH patients. We also sought to characterize the patients who had received β-blocker therapy and to compare their clinical presentation to that of patients without β-blocker therapy. We found no evidence that β-blocker therapy is associated with increased mortality in patients with PAH, challenging the notion that β-blockers should be avoided in this population. The propensity score analysis also suggested that there were no statistically significant differences in long-term mortality between propensity score-matched pairs of PAH patients with and without β-blocker use.
Methods

Study Population

We studied patients in the PHC registry, which was initiated in March 2004. This database has been described in detail previously. Briefly, the PHC registry was created as a customized patient database to longitudinally collect specific variables on all patients evaluated at a single United States practice at 3 different university hospitals (University of Illinois at Chicago, Rush University Medical Center, and University of Chicago Medical Center) beginning in 1982 and ongoing. Five physicians acquired all the clinical data. Data were collected by a chart review and entered using an Internet-based electronic data capture system. Patients were entered retrospectively from 1982 to February 2004 and prospectively from March 2004. The recruitment period for the current analysis ended in November 2013. Data entry occurred after the complete initial evaluation. For all variables, outliers were verified by a chart review to minimize data entry errors. The investigators collected mortality data after all other data had already been entered. Therefore, clinical data entry was performed blinded to eventual outcome. All new patients gave informed consent for participation in the registry during the initial evaluation. Prospective and established patients actively followed gave informed consent. The PHC received institutional review board approvals for enrollment of subjects.

From the PHC registry, we identified all adult subjects with PAH aged 18 years or older at the time of referral (n=718). PAH was defined per the current guidelines as mean pulmonary artery pressure ≥25 mmHg at rest, pulmonary capillary wedge pressure of ≤15 mmHg, and pulmonary vascular resistance (PVR) >5 Wood units. As per the World Health Organization clinical classification of pulmonary hypertension, patients were excluded if they had pulmonary venous hypertension diagnosed by pulmonary capillary wedge pressure >15 mmHg; obstructive lung disease diagnosed by reduced expiratory flow rates (forced expiratory volume in 1 second/forced vital capacity <70% predicted); more than mild interstitial lung disease diagnosed by typical appearance on computed tomography or total lung capacity <60% predicted; chronic pulmonary thromboembolic disease diagnosed by ventilation perfusion (V/Q) scan (other than normal or low probability), contrast-enhanced chest computed tomography, or pulmonary angiography if necessary; and pulmonary hypertension associated with sarcoidosis and other infiltrative diseases. Of the 718 patients with PAH, we excluded 154 patients in whom either we could not determine β-blocker use at the time of initial evaluation or those with incomplete data. The remaining 564 patients formed our total cohort.

Variables

The following baseline variables at the time of referral were analyzed for characterization of clinical phenotype: demographic data, comorbid conditions, World Health Organization functional class, baseline medications patients were taking at the time of enrollment in the PHC registry, and exercise treadmill testing using the Naughton-Balke protocol as a measure of exercise capacity. We analyzed the baseline echocardiographic and invasive hemodynamic variables obtained by right heart catheterization for characterization of the severity of PAH and RV function. The echocardiographic variables analyzed include presence of right atrial enlargement, presence of right ventricular hypertrophy, degree of right ventricular dysfunction (mild, moderate, and severe), tricuspid regurgitation jet velocity, presence of left atrial enlargement, left atrial dimension, left ventricular posterior and septal wall thickness, and left ventricular ejection fraction. The hemodynamic variables analyzed include mean right atrial pressure, right ventricular systolic and diastolic pressure, systolic, diastolic, and mean pulmonary artery pressure (mPAP), pulmonary capillary wedge pressure, CO, pulmonary artery saturation, and PVR.

Long-Term Management

All patients who responded to acute vasodilator challenge were treated with calcium-channel blockers. Initially, a positive response was defined as a 20% decrease in mPAP with an increase in CO; as of 2005, positive vasodilator response was defined as a decrease in mPAP >10 mmHg and to <40 mmHg, with unchanged or increased CO. Patients who did not respond to the acute vasodilator challenge received either monotherapy or combination therapy with endothelin antagonists, phosphodiesterase inhibitors, or prostacyclins, based on the severity of symptoms. All patients without contraindications were started on anticoagulation with warfarin to achieve a target international normalized ratio of 2–3. Patients with an arterial oxygen saturation of <90%, either at rest or during exercise, were prescribed supplemental nasal oxygen. In addition, patients received diuretics and digoxin as needed to treat symptoms of RVF. Patients who were on β-blockers for other indications at the time of initial evaluation were continued on it unless they had cardiogenic shock. Patients were followed closely every 6 to 12 months on an outpatient basis and more frequently if medically necessary.

Mortality

The primary outcome was all-cause mortality. Vital statistics were obtained for all patients by chart review and Social Security Death Index. For each death, the date of death was collected. In patients who were not identified as deceased using the Social Security Death Index, it was possible to establish vital status by chart review.

Statistical Analysis

All continuous variables are expressed as mean±standard deviation and categorical variables as frequency (percentage) unless otherwise noted. We compared the baseline demographic, clinical, echocardiographic, and hemodynamic characteristics of the total study cohort, stratified by β-blocker use. Continuous variables were analyzed using either a t test or Wilcoxon rank-sum test, and categorical variables were compared using χ2 or Fisher exact test where appropriate.

To reduce the effect of confounding caused by differences in baseline demographic, clinical, echocardiographic, and hemodynamic characteristics between PAH patients with and without β-blocker use, we used propensity score matching in combination with Cox regression modeling. A propensity score was estimated for each patient using a logistic regression model in which the dependent variable was β-blocker use and the covariates were age, sex, World Health Organization functional class, pathogenesis of pulmonary hypertension, history of hypertension, coronary artery disease, diabetes mellitus, history of obesity, end-stage renal disease, use of calcium-channel blockers, digoxin, aspirin, diuretics, angiotensin-converting enzyme inhibitor, right and left atrial enlargement and right ventricular hypertrophy by echocardiogram, invasive hemodynamic variables, including mean right atrial pressure, mPAP, pulmonary capillary wedge pressure, CO, and PVR. Patients were matched on estimated propensity scores, with replacement, using a nearest neighbor approach. A maximum caliper width of 0.2 of the pooled standard deviation of the logit of the propensity score [caliper=0.03] was used, as previously suggested.

We calculated the mean bias between the 2 treatment groups in 2 steps. First we calculated the bias for each covariate before and after matching between those treated with β-blockers and those not treated with β-blockers. Each bias was calculated as the standardized difference of the mean for continuous variables or standardized difference of the prevalence for categorical variables. We then took the arithmetic mean of the absolute standardized differences calculated to generate the mean bias.

Absolute difference in mortality between those with and without β-blocker use in the propensity score–matched cohort was compared using bootstrapped estimates with 1000 replications. We generated bootstrap estimates by sampling with replacement over 1000 repetitions from the matched sample after the study design as described previously. This nonparametric method is based on the assumption that our sample is representative of the population. By resampling our cohort with replacement in the matched sample, we generated 1000 unique samples. The reported estimates reflect the average treatment effect on the treated of β-blockers on mortality over these 1000 samples.

Next, mortality was compared between those with and without β-blocker use in the total cohort and the propensity-matched cohort, using Kaplan–Meier analysis and the log-rank test. The date of initial right heart catheterization was used as the date of entry into the study. Patients were censored at the time of death or when lost to follow up.
To further assess the effect of β-blocker use on all-cause mortality, Cox proportional hazard models were constructed, unadjusted, and adjusted for propensity score in the total cohort and in the matched cohort. To determine whether the use of β-blockers were protective mainly in patients for whom other neurohormonal and renin–angiotensin–aldosterone axis modifying therapies were coadministered, we compared the survival between those with and without β-blocker use in PAH patients who were on diuretics, aldosterone antagonists, or angiotensin-converting enzyme inhibitor/angiotensin receptor blockers (n=280). We tested the proportional hazards assumption by conducting individual likelihood ratio tests for each predictor. For each covariate, we created time-dependent covariates in the form of an interaction term, with the covariate being tested and a log-transformed function of time. We then serially tested each time-dependent covariate using a likelihood ratio test for significance at the 90% level of confidence.

All statistical analyses were performed using Stata (version 13, StataCorp LP, College Station, TX). The authors had full access to the data and take responsibility for their integrity. All authors have read and agree to the article as written.

**Results**

**Baseline Characteristics of the Unmatched Total Cohort**

Of the total 564 patients, 71 (13%) were on β-blocker therapy and 493 (87%) were not on β-blocker therapy at the time of initial evaluation. Figure 1 displays the name and the frequency of various β-blockers received by the PAH patients in our registry. Table 1 compares the baseline demographic and clinical characteristics between those with and without β-blocker use. PAH patients with β-blocker use were more likely to be older, more often had connective tissue associated and portopulmonary PAH, and less often had idiopathic, familial, and anorexigen-associated PAH. PAH patients receiving β-blockers also had higher prevalence of hypertension, obesity, and coronary artery disease. PAH patients with β-blocker use were more likely to be on angiotensin-converting enzyme inhibitor, diuretics, and aspirin, and less likely to be on digoxin. There was no significant difference in the use of PAH-specific medications at the time of initial evaluation. The severity of pulmonary hypertension and right ventricular dysfunction, measured by baseline echocardiographic and hemodynamic characteristics, were not different between those with and without β-blocker use (Table 2).

**Propensity Score**

Table 3 lists the odds ratio of the baseline characteristics that were independently associated with the use of β-blockers in patients with PAH. Hypertension, obesity, diuretic use, warfarin use, and higher PA systolic pressure were independently associated with increased use of β-blockers. However, idiopathic PAH, anorexigen-associated PAH, connective tissue disease–associated PAH, digoxin use, endothelin receptor antagonist use, and calcium-channel blockers use were independently associated with decreased use of β-blockers.

Of the 71 PAH patients with β-blocker use, 63 had an estimated propensity score that matched within the 0.03 caliper to 51 PAH patients without β-blockers use. Matching resulted in a reduction in mean bias from 19.4±16.9% in the total cohort to 7.9%±6.6% in the matched cohort. The standardized bias was <10% for all variables. After matching, there were no significant differences in baseline demographic, clinical, echocardiographic, and hemodynamic characteristics between those with and without β-blocker use (Table 1 and 2). Although the registry from which we collected this data spanned the period from 1982 to 2013, the patients

![Figure 1. Name and frequency of β-blockers used at baseline.](Image 1)
comprising our propensity score–matched cohort were all referred between the years 1993 and 2013.

Mortality
The median follow up time of the study cohort was 4.8 years (25th–75th percentile: 1.7–10.2 years). Over the course of follow up, 60% (339/564) of patients died in the total cohort. Among patients without β-blocker use, 60% (294/493) died and 63% (45/71) of those with β-blocker use died. In the propensity score–matched cohort, 57% (29/51) of patients without β-blocker use and 65% (41/63) of patients with β-blocker use died. Using bootstrap analysis with 1000 repetitions, we estimated that the mortality among patients taking β-blockers was 7 (95% confidence interval [CI], −30 to 44) percentage points higher than the mortality among patients not taking β-blockers, but this was not statistically significant (P=0.71).

Using Kaplan–Meier and Cox regression, in the total cohort, β-blocker use was associated with increased all-cause mortality in the unadjusted model (hazard ratio [HR] 1.4; 95% CI, 1.1–2.0), but was no longer significant after adjustment with the propensity score (HR 1.0; 95% CI, 0.7–1.5; Figure 2 and Table 4). In contrast to the total cohort, in the matched cohort, β-blocker use was not associated with increased all-cause mortality (HR 1.2; 95% CI, 0.8–2.0; Figure 3 and Table 4). Table 3 summarizes the results of the Cox proportional hazards analysis in both cohorts. There was

<table>
<thead>
<tr>
<th>Table 2. Baseline Echocardiographic and Hemodynamic Characteristics by β-Blocker Use in the Total and Propensity-Matched Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>Characteristics</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Echocardiography</td>
</tr>
<tr>
<td>RA enlargement, n (%)</td>
</tr>
<tr>
<td>RV hypertrophy, n (%)</td>
</tr>
<tr>
<td>RV Function, n (%)</td>
</tr>
<tr>
<td>Normal</td>
</tr>
<tr>
<td>Mildly reduced</td>
</tr>
<tr>
<td>Moderately reduced</td>
</tr>
<tr>
<td>Severely reduced</td>
</tr>
<tr>
<td>Tricuspid regurgitation jet velocity, m/sec</td>
</tr>
<tr>
<td>Right-left atrial shunt, n (%)</td>
</tr>
<tr>
<td>LA enlargement, n (%)</td>
</tr>
<tr>
<td>LA size, mm</td>
</tr>
<tr>
<td>LV posterior wall thickness, mm</td>
</tr>
<tr>
<td>LV septal wall thickness, mm</td>
</tr>
<tr>
<td>LV ejection fraction, %</td>
</tr>
<tr>
<td>Treadmill Exercise Testing</td>
</tr>
<tr>
<td>Exercise capacity, metabolic equivalents</td>
</tr>
<tr>
<td>O2 saturation at rest</td>
</tr>
<tr>
<td>O2 saturation postexercise</td>
</tr>
<tr>
<td>Hemodynamics</td>
</tr>
<tr>
<td>Mean RA pressure, mm Hg</td>
</tr>
<tr>
<td>RV systolic pressure, mm Hg</td>
</tr>
<tr>
<td>RV diastolic pressure, mm Hg</td>
</tr>
<tr>
<td>PA systolic pressure, mm Hg</td>
</tr>
<tr>
<td>PA diastolic pressure, mm Hg</td>
</tr>
<tr>
<td>Mean PA pressure, mm Hg</td>
</tr>
<tr>
<td>PCWP, mm Hg</td>
</tr>
<tr>
<td>Cardiac output, l/min</td>
</tr>
<tr>
<td>PA saturation, %</td>
</tr>
<tr>
<td>PVR, WU</td>
</tr>
</tbody>
</table>

LA indicates left atrium; PA, pulmonary artery; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; RA, right atrium; RV, right ventricle; and WU, wood units.
no difference in survival between those with (n=53) and without (n=227) β-blocker use when we restricted our analysis to only those who were on diuretics, aldosterone antagonists, or angiotensin-converting enzyme inhibitor/angiotensin receptor blockers (HR adjusted for propensity score, 0.97; 95% CI, 0.63–1.49; Figure 4).

Patients were enrolled in the PHC registry over a substantial period of time (1982–2013), which could have potentially introduced a bias caused by difference in practice patterns. Thus, we did a post hoc analysis of our matched sample to determine the difference in referral dates between our matched patients. The median difference in referral dates was 1812 days (4.96 years). The smallest difference was 11 days and the largest was 6763 days. We then excluded matches where referral dates were >5 years apart (median difference in date of referral between the study cohorts) and subsequently excluded 31/63 (49%) pairs in our matched sample. Similar to our total matched cohort, in this cohort also there was no difference in survival by Kaplan–Meier analysis between those with and without β-blocker use (Figure 5), and β-blocker use was not associated with a statistically significant increase in mortality (HR adjusted for propensity score, 1.59; 95% CI, 0.80–3.17).

Discussion

In this study of a well-characterized, large cohort of PAH patients, we found that β-blocker use is not uncommon in PAH patients, despite severe pulmonary hemodynamics. Despite severe PAH and right ventricular dysfunction, there was no statistically significant difference in long-term all-cause mortality between propensity score–matched pairs of PAH patients with and without β-blocker use.

The suggestion that β-blockers may have deleterious effects and are contraindicated in patients with PAH is based on the concept that the contractile reserve of the pressure-overloaded RV is significantly reduced in PAH, requiring patients to be dependent on their heart rate to maintain CO. In support of this, Provencher et al reported that withdrawal of β-blockers improved exercise capacity and right heart hemodynamics in 10 patients with portopulmonary hypertension who were receiving β-blockers for esophageal variceal bleeding prophylaxis. Compared with baseline, 9 out of the 10 patients had an increase in 6 minute walking distance and CO with a reduction in PVR 2 months after withdrawal of β-blockers. The increase in CO was driven solely by an increase in heart rate with no significant change in stroke volume.
of referral.

- blocker use

Figure 5. Comparison of Kaplan–Meier survival by $\beta$-blocker use in PAH-induced isolated RVF by inhibiting neurohor- 

monal activation.14,15,28 A small cohort study evaluated PAH 

patients with and without $\beta$-blocker therapy at presentation 

and found no detrimental effect of $\beta$-blockers.26,27 Contrary to these findings, preclinical animal experiments 

were receiving the first generation, nonselective $\beta$-blocker 

propranolol that perhaps has a greater bronchial and myocar-

dial depressive effect than the currently available selective $\beta$-blockers. However, this study did not adjust for the difference in baseline characteristics between those with and without $\beta$-blocker use.

Our study confirms these clinical findings in a large well-

characterized cohort of patients with severe PAH with long-
term follow up (median follow up time, 4.7 years). Additionally, we used propensity score matching in combination with Cox regression modeling to reduce confounding caused by differences in baseline demographic, clinical, echocardiographic, and hemodynamic characteristics between PAH patients with and without $\beta$-blocker use. Although there was a crude difference in survival between those with and without $\beta$-blocker in the total unmatched cohort, this difference was no longer significant after adjusting for the propensity score. Moreover, $\beta$-blocker use was not associated with increased all-cause mortality in the propensity score–matched cohort. We also did not observe difference in mortality between those with and without $\beta$-blocker use even when we restricted our analysis to only those on other conventional heart failure therapy.

In our registry, 13% (71/564) of PAH patients were on $\beta$-blockers for treatment of concomitant cardiovascular dis-

case. Using multivariable logistic regression, we found that the odds ratio for $\beta$-blocker use is significantly higher in PAH patients with coexisting history of hypertension, obe-
sity, diuretic use, warfarin use, and higher pulmonary artery systolic pressure on right heart catheterization. The exact mechanism behind the association between $\beta$-blocker use and warfarin use is not clear. Only 8 out of the 564 patients were in atrial fibrillation at the time of initial enrollment in our reg-

istry. In our experience, once given a diagnosis of PAH, the 

medication is often started for this indication before referral to a tertiary PAH center. However, it is possible that some patients were on warfarin for paroxysmal atrial fibrillation at the time of referral to our center. Our registry does not capture the intent of therapy initiation. It also seems that presence of concomitant cardiovascular disease have outweighed the theo-

retical risk associated with $\beta$-blocker therapy and resulted in its use in PAH patients.

This study has several limitations that merit discussion. First, many of the patients diagnosed before 2004 were entered retrospectively, which has inherent limitations. This is a single center study and the results may not be generalizable. We collected data only on the use of $\beta$-blockers at baseline; thus, we 
could not calculate exposure time for $\beta$-blockers. However, it is our practice to continue $\beta$-blockers in PAH patients who were receiving it for other indications unless they have hypo-
tension or acute decompensated RVF. Second, we did not collect complete exercise testing data to determine whether there was any difference in heart rate and CO response to exer-
cise between PAH patients with and without $\beta$-blocker use. However, there was no significant difference in change in oxy-
gen saturation with exercise (surrogate marker of RV reserve) between the 2 groups. Third, we did not collect the details of

Figure 4. Comparison of Kaplan–Meier survival by $\beta$-blocker use in pulmonary arterial hypertension patients on other conventional heart failure therapy. HF indicates heart failure; other conven-
tional HF therapy includes diuretics, aldosterone antagonists, or angiotensin-converting enzyme inhibitor/angiotensin receptor blockers.

This small study questioned the utility of $\beta$-blockers in this 
specific PAH population; however, it was small and lacked a sensitivity analysis with a long-term comparison between 
those who continued $\beta$-blocker use and those who discon-

This study has several limitations that merit discussion. First, many of the patients diagnosed before 2004 were entered retrospectively, which has inherent limitations. This is a single center study and the results may not be generalizable. We collected data only on the use of $\beta$-blockers at baseline; thus, we could not calculate exposure time for $\beta$-blockers. However, it is our practice to continue $\beta$-blockers in PAH patients who were receiving it for other indications unless they have hypotension or acute decompensated RVF. Second, we did not collect complete exercise testing data to determine whether there was any difference in heart rate and CO response to exercise between PAH patients with and without $\beta$-blocker use. However, there was no significant difference in change in oxygen saturation with exercise (surrogate marker of RV reserve) between the 2 groups. Third, we did not collect the details of

Figure 5. Comparison of Kaplan–Meier survival by $\beta$-blocker use in the propensity score–matched cohort after adjusting for date of referral.
the cause of death other than whether it was PAH related or not. Hence, we could not determine whether there was any difference in mortality specifically related to RVF between those with and without β-blocker use. Fourth, although the 2 groups were matched using estimated propensity scores, we cannot completely exclude residual confounding factors that might have influenced the results. Finally, although the low sample size after propensity score matching decreases the power for our study, to the best of our knowledge, this is the largest reported cohort of PAH patients with and without β-blockers use. A noninferiority study design might have provided more power to demonstrate that β-blocker use is not statistically associated with increased mortality in PAH. Nonetheless, we used a superiority design because of lack of an active control group for comparison to PAH patients taking β-blockers and because of the lack of previous published estimates of mortality in patients with PAH with which to choose a noninferiority margin. The estimates presented here should help inform future studies in selecting an appropriate noninferiority margin. Hence, our analysis is only hypothesis generating, and β-blockers should not be used in PAH patients based solely on these results.

In conclusion, β-blockers are often used in patients with severe PAH for other existing illness in the PHC registry. β-blockers use is not associated with statistically significant increase in long-term all-cause mortality using propensity score matching analysis. Prospective clinical trials that assess the safety and efficacy of β-adrenergic receptor antagonists in PAH are needed in the future.

Acknowledgments

We thank Dr John E. Connett, PhD, Professor, Division of Biostatistics, School of Public Health, University of Minnesota for advice on the statistical methodology.

Sources of Funding

This study is supported by funding from the Lillehei Heart Institute, Minneapolis, Minnesota.

Disclosures

Thenappan Thenappan has received honoraria for continuing medical education (CME) from Medscape, Actelion, Gilead, Medtronic, Novartis, Lung Biotechnology, and Reata have provided funding to the University of Chicago to support Dr Gomberg-Maitland’s conduct of clinical trials. Dr Gomberg-Maitland has served as a consultant for Actelion, Gilead, Medtronic, Belcherophan (formerly known as Ikaria), and United Therapeutics as a member of steering committees and Data Safety Monitoring Board/event committees. She has received honoraria from Medscape and AB Comm. The other authors report no conflicts.

References


CLINICAL PERSPECTIVE

Pharmacological blockade of the β-adrenergic receptor with β-blockers is one of the main treatment strategies in left ventricular systolic dysfunction. However, the safety and efficacy of β-blocker therapy in isolated right ventricular failure associated with pulmonary arterial hypertension (PAH) is unclear. There is a theoretical concern for worsening right ventricular failure with β-blockers in patients with PAH because they are highly dependent on the heart rate to maintain their cardiac output. Human studies, thus far, have reported conflicting results with respect to the safety and efficacy of β-blockers in PAH. We evaluated the association between β-blocker therapy and long-term outcomes in 564 patients with PAH in our Pulmonary Hypertension Connections registry. Propensity score matching was used to match pairs of PAH patients with and without β-blocker use. We found that β-blockers were frequently used in patients with severe PAH in our Pulmonary Hypertension Connections registry. Compared with PAH patients without β-blocker use, those with a β-blocker use were older, had higher prevalence of comorbidities, and were more often on diuretics, digoxin, and angiotensin-converting enzyme inhibitors. The severity of PAH and right ventricular failure was similar between those with and without β-blocker use. There was no statistically significant difference in long-term mortality between propensity score–matched pairs of PAH patients with and without β-blocker use. Prospective clinical trials that assess the safety and efficacy of β-adrenergic receptor antagonists in PAH are needed in the future.
β-Blocker Therapy Is Not Associated With Adverse Outcomes in Patients With Pulmonary Arterial Hypertension: A Propensity Score Analysis
Thenappan Thenappan, Samit S. Roy, Sue Duval, Cherylanne Glassner-Kolmin and Mardi Gomberg-Maitland

_Circ Heart Fail._ 2014;7:903-910; originally published online October 2, 2014;
doi: 10.1161/CIRCHEARTFAILURE.114.001429
_Circulation: Heart Failure_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2014 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-3289. Online ISSN: 1941-3297

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circheartfailure.ahajournals.org/content/7/6/903

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation: Heart Failure_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation: Heart Failure_ is online at:
http://circheartfailure.ahajournals.org//subscriptions/